Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apotea AB (publ)CHIX:APOTES 18 EV-to-EBIT is 24.43 as of Jul. 29, 2026, which is 16% below its 10-year median of 29.06. GuruFocus rates CHIX:APOTES with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 471 Healthcare Providers & Services companies, Apotea AB (publ) ranks worse than 69.43% on this metric.
The historical rank and industry rank for Apotea AB (publ)'s EV-to-EBIT or its related term are showing as below:
CHIX:APOTEs'
s EV-to-EBIT Range Over the Past 10 Years
Min: 20.67 Med: 29.06 Max: 40.35
Current: 24.44
During the past 5 years, the highest EV-to-EBIT of Apotea AB (publ) was 40.35. The lowest was 20.67. And the median was 29.06.
CHIX:APOTEs's EV-to-EBIT is ranked worse than 69.43% of 471
companies
in the Healthcare Providers & Services industry
Industry Median: 15.74
vs CHIX:APOTEs: 24.44
Apotea AB (publ) (CHIX:APOTEs) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Apotea AB (publ)'s Enterprise Value for the quarter that ended in Jun. 2026 was kr6,977 Mil.
Apotea AB (publ)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr322 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apotea AB (publ) EV-to-EBIT Related Terms
Apotea AB (publ) EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Apotea AB (publ)'s EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Apotea AB (publ)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apotea AB (publ) EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Apotea AB (publ)'s EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Apotea AB (publ)'s EV-to-EBIT falls into.
Apotea AB (publ)'s current Enterprise Value is kr7,872 Mil.
Apotea AB (publ)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr322 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apotea AB (publ) (CHIX:APOTES) has a EV-to-EBIT of 24.43 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Apotea AB (publ) and its competitors. This is 16% below median its historical median of 29.06. Over the past decade, Apotea AB (publ)'s EV-to-EBIT has ranged from 20.67 to 40.35. According to the industry distribution chart, Apotea AB (publ) ranks #327 out of 471 companies in the Healthcare Providers & Services industry, placing it in the top 69.4%.
Is Apotea AB (publ)'s EV-to-EBIT too high?
Apotea AB (publ)'s current EV-to-EBIT of 24.43 is 16% below median its 10-year median of 29.06. Over the past 10 years, this metric has ranged from a low of 20.67 to a high of 40.35. The Healthcare Providers & Services industry median EV-to-EBIT is 15.74. Apotea AB (publ)'s value of 24.43 is 55.2% above this industry median. Based on the distribution chart, Apotea AB (publ) ranks #327 out of 471 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s EV-to-EBIT compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Apotea AB (publ) ranks #327 out of 471 companies for EV-to-EBIT. This places Apotea AB (publ) in the lower half of its industry. The industry median EV-to-EBIT is 15.74. Apotea AB (publ)'s value of 24.43 is 55.2% above this benchmark. Historically, Apotea AB (publ)'s own EV-to-EBIT has ranged from 20.67 to 40.35 over the past decade. While the company's 10-year median is 29.06 vs. the industry median of 15.74, Apotea AB (publ) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.74, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apotea AB (publ)'s current EV-to-EBIT of 24.43 is 55.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Apotea AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apotea AB (publ)'s current EV-to-EBIT is 24.43, which is 16% below median its own 10-year median of 29.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (CHIX:APOTES) has a current EV-to-EBIT of 24.43. The current EV-to-EBIT is 24.43, which is 16% below median its 10-year median of 29.06 and 55.2% above the Healthcare Providers & Services industry median of 15.74. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Apotea AB (publ) (CHIX:APOTES), the current EV-to-EBIT is 24.43 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score
Get the complete analysis for CHIX:APOTES
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:APOTES has been successfully added to your 
